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BM = basement membrane; ECM = extracellular matrix; EGF = epidermal growth factor; ER = estrogen receptor; ERE = estrogen response
element; ERKO = estrogen receptor knockout; IGF-I = insulin-like growth factor-I; IGFBP = insulin-like growth factor binding protein; PR = proges-
terone receptor.
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Introduction
Postnatal mammary gland development and function are
highly dependent upon the actions of the ovarian hor-
mones, estrogen and progesterone [1]. In estrogen recep-
tor knockout (ERKO) mice only a rudimentary mammary
gland is present at birth and no further development
occurs postnatally [2]. To determine whether estrogen
receptor (ER) is required in stromal tissue, epithelial tissue
or both for normal mammary gland development, Cunha et
al. [3] have surgically transplanted wild-type (ER+/+) or
ERKO (ER–/–) epithelial tissue with wild-type or ERKO
stromal tissue under the kidney capsule of athymic nude
mice. These authors reported that ER+/+ stroma was
required for normal mammary ductal morphogenesis, but
ER+/+ epithelium was not. These results corroborate in
vitro studies that have demonstrated that estrogen-depen-
dent mammary epithelial proliferation and/or ductal mor-
phogenesis is mediated through the paracrine action of
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and breast cancer growth and progression.
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estrogen-induced, stroma-derived factors. Stromal cells
appear to influence epithelial cell behavior by the secre-
tion of growth factors and/or by altering the composition
of the extracellular matrix (ECM) in which epithelial cells
reside [4–6]. Previously we have reviewed the regulation
and action of autocrine and paracrine growth factors
(including the epidermal growth factor, insulin-like growth
factor, hepatocyte growth factor and fibroblast growth
factor families) involved in ovarian steroid-mediated epithe-
lial–stromal interactions [4]. A recent report has also
demonstrated that keratinocyte growth factor mRNA and
protein are increased by estrogen in mammary stroma,
although it is not clear what effect keratinocyte growth
factor has on mammary gland development or differentiation
[7]. In the past few years, several studies have revealed
information about basement membrane (BM) ECM proteins
and their cellular receptors: they regulate cell proliferation,
differentiation and apoptosis; they are secreted and/or regu-
lated by complex epithelial-stromal interactions; they are
regulated by ovarian steroids; and they regulate ovarian
steroid action. Hansen and Bissell [8] have recently
reviewed experimental models that have been developed to
study the effects of ECM, steroids and growth factors on
breast cancer. This review will focus on recent findings, by
us and other investigators, about ECM composition and
integrin expression in vitro and in vivo in relation to the pro-
liferative responses of normal and neoplastic mammary
epithelial cells to estrogen and progestins.
Although animal models, including the ERKO mice study
described above, have been invaluable in determining a
requirement for epithelial–stromal interactions in ovarian
steroid-mediated mammary morphogenesis, cell culture
models have been useful to elucidate the underlying
mechanisms of cell–cell interactions and the cell types
involved. Many previous culture studies, however, that
were performed to address these questions in the
mammary gland were carried out in the presence of serum
or impure supplements (e.g. matrigel, fetuin, pituitary
extracts). Serum and these supplements contain ECM
proteins, growth factors and other biologically relevant
components that have impeded our understanding of the
specific mechanisms by which stromal cells contribute to
the acquisition and loss of ovarian hormone responsive-
ness. We carried out the in vitro studies, described in this
review, under serum-free, defined culture conditions. This
has allowed us to address these issues more precisely.
Influence of ECM proteins on steroid-induced
proliferation in vitro
ECM proteins work in concert with systemic hormones
and autocrine/paracrine growth factors to regulate prolif-
eration, differentiation and apoptosis. Mammary epithelial
cells and myoepithelial cells are separated from stromal
cells by a BM composed of ECM proteins. The origin of
the BM was once considered to be synthesized exclu-
sively by epithelial cells, but now researchers have deter-
mined, in several epithelial tissues, that the BM requires
epithelial stromal interactions and that often most resident
ECM proteins in the BM are synthesized by mesenchymal
or stromal cells. Mammary adipocytes have been shown to
produce laminin and heparan sulfate proteoglycans;
fibroblasts produce collagen I, fibronectin and tenascin in
vivo [9,10]. Keely et al. [10] have presented compelling
evidence based upon in situ hybridization and immunocy-
tochemical analyses, that mammary stromal cells are pri-
marily responsible for the expression of collagen I,
collagen IV and laminin in the mammary gland. Perhaps
the most meticulous examination of the cellular origin of
BM synthesis and deposition has occurred in the gut.
Simon-Assman et al. have found that BM components of
the gut are of dual origin, with heparan sulfate proteogly-
cans being produced primarily by epithelial cells, while
collagen and laminin were produced mainly by stromal
cells [11]. Using novel mouse/chick tissue recombinants
and analyzing ECM expression with species-specific anti-
bodies, they have further determined that alpha-2 and
alpha-4 laminin chains are produced exclusively by stromal
cells. The laminin alpha-5 chain, however, is expressed by
both epithelial and stromal cells in a developmentally regu-
lated pattern. These studies demonstrate a complex inter-
action between epithelial and stromal cells in the formation
of the BM [12]. These researchers have also demon-
strated that the formation of a BM requires contact
between epithelial and mesenchymal cells. Similar studies
in the mammary gland are lacking. Taken together,
however, these studies strongly suggest that
epithelial–stromal interactions are critical for the formation,
and perhaps regulation, of the epithelial BM in the
mammary gland. ECM proteins, therefore, like growth
factors, can function as a stromal-derived paracrine factor
that may influence epithelial behavior.
To determine if ECM proteins affect ovarian steroid action
on mammary epithelium, we have investigated the interac-
tions between ECM proteins (collagens I and IV, laminin,
fibronectin and tenascin) and estrogen and progestin in
serum-free primary cell culture of mouse mammary epithe-
lial cells [5]. These studies demonstrated that ovarian
steroid-induced proliferation of epithelial cells only
occurred when epithelial cells were cultured on certain
ECM proteins. Epithelial cells derived from adult, virgin
mice proliferated in response to the progestin R5020, only
on fibronectin and collagen IV (Fig. 1). The response to
R5020 on these matrices could not be explained by differ-
ences in ER or progesterone receptor (PR) levels, or by
differences in cell attachment. Estrogen does not induce
proliferation of mammary epithelial cells in vitro, unless
epithelial cells are co-cultured with stromal cells [13]. In
monoculture, however, epithelial cells also exhibited a pro-
liferative response to estrogen, albeit inconsistently, on
fibronectin, suggesting that the estrogen-inducedc
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response may require several stromal signals, including
ECM. Epithelial cells from pregnant mice were not respon-
sive to estrogen or R5020, on any matrix. Thus, respon-
siveness to ovarian hormones was first and foremost
dependent upon the inherent state of mammary gland dif-
ferentiation, but within the framework of mammary gland
differentiation, ECM molecules can modulate hormonal
responsiveness.
Interactions among growth factors, ovarian
hormones and ECM proteins in vitro
There is considerable evidence to indicate that the prolif-
erative effects of estrogen are mediated indirectly by
locally produced stroma-derived growth factors [4]. There
is also evidence that growth factors can synergize with
estrogen or can activate ER in the absence of ligand [14].
To address this issue we have investigated the effects of
specific ECM proteins on the proliferative responses to
epidermal growth factor (EGF) and insulin-like growth
factor-I (IGF-I), and their interactions with estrogen and
R5020 [6]. All ECM proteins tested in these experiments
(collagens I and IV, fibronectin and laminin), promoted
highly synergistic proliferation between EGF and IGF-I
(Fig. 2a) This synergism was accomplished through
several mechanisms, including increased expression of
growth factor receptors. EGF receptor levels were signifi-
cantly increased on collagen I and fibronectin, whereas
IGF-I receptor levels were increased on all of the ECM
proteins tested, with the greatest increase observed on
Available online http://breast-cancer-research.com/content/3/6/365
Figure 1
The effect of progestin (R5020) and extracellular matrix proteins on
mammary epithelial DNA synthesis. Epithelial cells derived from
nulliparous or pregnant mice were plated on poly-L-lysine (PL),
collagen I (Col I), fibronectin (FN), tenascin (TN), laminin (LN), or
collagen IV (Col IV) in serum-free medium. At 24 hour post-plating, the
media was changed to either the control media or a media containing
R5020 (20 nM). 3H-thymidine incorporation into DNA was determined
48 hour later. The percent increase was obtained by dividing counts
per min/mg DNA of cells cultured in the presence of R5020 by counts
per min/mg DNA of cells cultured in the absence of R5020. *P < 0.05
that R5020 stimulated proliferation of nulliparous derived cells on FN
and Col IV. (Adapted from [3] with permission from Endocrinology).
Figure 2
Epithelial cell proliferation on different extracellular matrix proteins
induced by epidermal growth factor plus insulin-like growth factor-I.
Epithelial cells derived from nulliparous mice were plated as described
in Fig. 1a. (a) At 24 hour post-plating, the media was changed to
control (no growth factors), or a media containing EGF (50 ng/ml), IGF-I
(300 ng/ml) or EGF+IGF-I (50 ng/ml + 300 ng/ml). 3H-thymidine
incorporation into DNA was determined 24 hour later. *P < 0.01 that on
poly-L-lysine, proliferation in EGF+IGF-I treated group is greater than in
EGF- or IGF-I-treated groups. **P < 0.01 that on all ECM proteins,
proliferation in EGF+IGF-I is greater than in EGF- or IGF-I-treated
groups on ECM proteins and poly-L-lysine. (b) Epithelial cells were
plated on indicated ECM proteins in medium without growth factors or
hormones (control), with growth factors (GF: EGF 25 ng/ml + IGF-I
100 ng/ml), with or without estrogen (E2, 10 nM) and/or R5020 (23
nM). *P = 0.05 that values obtained with EGF + IGF-I + R5020 on LN
and with EGF + IGF-I + E + R5020 on Col I and LN are significantly
lower than EGF + IGF-I. (Adapted from [4] with permission from
Endocrinology). Col, collagen; E2, estrogen; ECM, extracellular matrix;
EGF, epidermal growth factor; FN, fibronectin; GF, growth factors; 
IGF-I, insulin-like growth factor-I; LN, laminin; PL, poly-L-lysine.laminin. The synergism between the two growth factors
was also mediated by ECM effects on IGF-I binding protein
(IGFBP) levels. IGFBP-2 and -3 were increased in cells
cultured with IGF-I alone, but decreased in the presence of
EGF + IGF-I. The cells cultured on fibronectin, however,
did not show this trend. Overall, levels of IGFBPs were
lower in cells cultured on fibronectin. The decrease in
IGFBPs that occurred with EGF + IGF-I or in the pres-
ence of fibronectin may facilitate increased IGF-I activity.
No additive or synergistic proliferative effect was observed
with EGF, IGF-I or EGF + IGF-I and estrogen or R5020. In
fact, the opposite was observed; estrogen + R5020
decreased proliferation in an ECM-dependent manner
when added with EGF + IGF-I to cells cultured on colla-
gen I or laminin (Fig. 2b). In vivo studies investigating the
expression of and response to IGF-I have shown that IGF-I
is important for ductal elongation in the immature gland,
but not during pregnancy [15]. In contrast, PR levels are
low and progestins are ineffective in stimulating prolifera-
tion at this stage of development, but play an important
role in alveolar morphogenesis during pregnancy [16].
Thus, the expression of IGF-I and IGF-I receptors and PR
and progestin responsiveness are inversely related and
appear to be important in two distinct stages of prolifera-
tion: ductal elongation versus alveolar morphogenesis. In
this context, our findings that R5020 + estrogen reduce
the proliferative response to EGF + IGF-I in vitro also
suggest that progestins may have an inhibitory effect on
IGF-I-induced proliferation in vivo. The observations from
these studies demonstrate that various stroma-derived
ECM proteins regulate specific aspects of the response
and are necessary for EGF–IGF-I synergism. Furthermore,
this synergism may be reduced by progestins.
Developmental and hormonal regulation of
fibronectin and its α α5β β1 integrin, in vivo
Since specific ECM proteins influence mammary epithelial
cell proliferative response to hormones and growth factors
in vitro, it was of interest to investigate their roles in vivo.
Toward this end, we have analyzed the in vivo spatial and
temporal concentrations of fibronectin, collagens I and IV
and laminin during postnatal development, and the effects
of ovariectomy and estrogen and progesterone treatment
on ECM and integrin expression [17].
We observed that the levels of the ECM protein
fibronectin and its classic receptor, the α5β1 integrin,
are developmentally and hormonally regulated in the
normal mouse mammary gland. Western blot analysis
revealed that fibronectin levels increased 3-fold
between the prepubertal state and sexual maturity,
remaining high during pregnancy and lactation.
Fibronectin increased only in intact glands in associa-
tion with the epithelium. In contrast to fibronectin, the
levels of collagens I and IV and laminin did not exhibit
major changes during development. Fibronectin levels
decreased by 70% after ovariectomy and were
increased 1.5- and 2-fold by treatment with estrogen or
estrogen + progesterone, respectively (Fig. 3).
During development, α5β1 integrin levels increase from
puberty to early pregnancy and decrease at late preg-
nancy and lactation (Fig. 4a). Analysis of hormonal regula-
tion of the α5β1 integrin in the adult, virgin mammary
gland revealed that the levels of the α5β1 integrin was sig-
nificantly down-regulated by ovariectomy and rapidly (by
24 hours after treatment) up-regulated after estrogen +
progesterone treatment in both mammary epithelial and
myoepithelial cells (Fig. 4b). The subcellular localization
of the α5β1 integrin was also developmentally and hor-
monally regulated. During periods of active proliferation,
such as puberty and early pregnancy, and in ovariec-
tomized adult mice following estrogen + progesterone
treatment, the α5β1 integrin was preferentially localized to
the basal surface of the cell. Hormone-dependent basal
localization of the α5β1 integrin is suggestive of binding to
adjacent BM proteins and is consistent with integrin acti-
vation and signaling during estrogen-mediated or proges-
terone-mediated mitogenesis. High basal localization of
α5β1 was reduced during late pregnancy and lactation,
Breast Cancer Research    Vol 3 No 6 Haslam and Woodward
Figure 3
Fibronectin expression in normal mammary gland as a function of age
and developmental state. Frozen sections of mammary glands from
immature, pubertal, sexually mature (3-, 5-, 10-week-old, respectively),
or pregnant and lactating mice were immunostained with antibody to
fibronectin. Fluorescence staining intensity (measured as average pixel
brightness) was quantitated for epithelial and stromal cells as
previously described [20]. *P < 0.05 that 10-week-old, pregnant and
lactating epithelial staining intensity is greater than that of 3- or 5-
week-old mice.developmental stages characterized by low proliferation.
This leads us to hypothesize that fibronectin and the α5β1
integrin play an important role in estrogen-dependent and
estrogen + progesterone-dependent regulation of epithe-
lial cell proliferation. Because α5β1 integrin levels were
more closely correlated with proliferation than fibronectin
levels, and because the α5β1 integrin was more rapidly
regulated by ovarian steroids than fibronectin, it is likely
that regulation of integrin expression represents a more
dynamic mechanism for controlling cellular proliferation
and morphogenesis than the synthesis and degradation
of ECM proteins.
ECM effects on estrogen action in human
breast cancer cells in vitro and in vivo
Deciphering the complex interactions involved in growth
factor-dependent and ovarian-steroid-dependent prolifera-
tion in the normal mammary gland has specific relevance
to understanding the alterations in the growth control that
occur in breast cancer. Loss of estrogen responsiveness
in breast cancer cells is a major problem in the treatment
of this disease. Long-term treatment of estrogen-respon-
sive breast cancer with antiestrogen has not been effec-
tive because tumors eventually become antiestrogen resis-
tant [18]. Despite the critical importance to breast cancer
treatment, the mechanism(s) leading to loss of estrogen
responsiveness and antiestrogen resistance is poorly
understood.
In breast cancer, the stromal cells surrounding tumors
have increased or altered the expression of many ECM
proteins that change with breast cancer progression
[19–21]. However, little is known about how specific ECM
proteins might affect estrogen action in breast cancer
cells. To address this question, we have studied the
effects of various ECM proteins on estrogen-induced pro-
liferation in two ER positive human breast cancer cell lines
(MCF-7, T47D) in serum-free cell culture [22]. We found
that one ECM protein, laminin, specifically inhibited estro-
gen-induced proliferation and estrogen-induced PR induc-
tion in MCF-7 and T47D cells (Fig. 5a,b). The effect of
laminin was specific for estrogen since it did not inhibit the
proliferative response to the growth factors, EGF or IGF-I.
Our results indicate that the inhibition of estrogen action
by laminin is a postreceptor, postbinding event because
ER concentration and ER binding are not altered by
Available online http://breast-cancer-research.com/content/3/6/365
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Figure 4
Cellular localization and ovarian steroid regulation of α5β1 integrin in mouse mammary glands during development. (a) Frozen sections of mammary
glands from immature, pubertal, sexually mature (3-, 5-, 10-week-old, respectively), early pregnant (9–12 days), late pregnant (19–21 days) and
lactating (7–10 days) mice were immunostained with antibody to the α5β1 integrin. Note that staining is seen around ducts at 5 and 10 weeks of
age and around alveoli in early pregnant mice. No staining was seen at 3 weeks of age or at late pregnancy and lactation. Mag. 100X. 
(b) Mammary glands were removed from 10-week-old mice that were ovary intact (intact), ovariectomized for 1 week (OVX), or OVX given a single
i.p. injection containing 17β-estradiol (1 µg) + progesterone (1 mg) (E + P) and sacrificed 24, 48 or 72 hour later. Frozen sections were stained
with antibody to α5β1 integrin and fluorescence staining intensity (measured as average pixel brightness) was quantitated [20]. *P < 0.05 that OVX
α5β1 integrin staining intensity is lower than intact. **P < 0.05 that at 24, 48, and 72 hr post E + P injection, α5β1 integrin staining intensity is
greater than OVX.laminin, but estrogen induction of estrogen-response-
element-mediated transcription is inhibited (Fig. 5c).
Tumor ECM microenvironment may thus influence epithe-
lial cell responsiveness to hormones and may therefore
lead to hormone insensitivity without the loss of hormone
receptors. These studies also indicate that these ER positive
cells may still be highly responsive to the mitogenic effects
of growth factors and this provides a plausible explanation
Breast Cancer Research    Vol 3 No 6 Haslam and Woodward
Figure 5
Effects of laminin on estrogen-induced proliferation, progesterone receptor regulation and estrogen receptor activity in ER positive human breast
cancer cell lines. (a) MCF-7 and T47D cells were cultured in serum-free medium containing EGF (5 ng/ml), IGF-I (25 ng/ml) on various ECM
proteins. Cells were pre-treated with 200 nM ICI 182,780 for 48 hour followed by no treatment (control) or 17β-estradiol (20 nM); 3H-thymidine
incorporation into DNA was determined 21 hour later. *P < 0.05 that estrogen-treated groups are greater than control-treated groups. (b) MCF-7
cells were cultured in serum-free medium in the absence (control) or presence of estrogen (10 nM) for 3 days. Progesterone receptor
concentrations were determined by specific 3H-R5020 binding assay. *P < 0.05 that estrogen-treated groups are greater than control groups. (c)
MCF-7 cells were transfected with estrogen response element (tk109-luc) and β-galactosidase plasmids. Luciferase activity was measured 24
hour after ICI 182,780 (200 nM), control or estrogen (10 nM) treatment. Luciferase activity was normalized to transfection efficiency determined by
β-galactosidase activity/cell. *P < 0.05 that estrogen-treated groups are greater than control groups. **P < 0.05 that estrogen-treated LM group is
less than estrogen-treated Col I or FN groups. (Adapted from [15] with permission from Endocrinology). Col, collagen; FN, fibronectin; LN, laminin;
PL, poly-L-lysine; VN, vitronectin.for the growth of ER positive breast cancer cells that are
estrogen-independent and/or antiestrogen resistant.
We have also investigated the effects of ECM proteins on
estrogen responsiveness of breast cancer cells in vivo.
MCF-7 tumor cells were mixed with collagen I or laminin or
both prior to implantation into athymic nude mice. Follow-
ing tumor cell implantation, all mice received exogenous
estrogen via estradiol-containing pellets, and tumor
growth was monitored. MCF-7 cells treated with collagen I
alone grew rapidly, whereas tumors cells treated with
laminin exhibited dramatically reduced growth; tumors
cells treated with collagen I + laminin grew at an interme-
diate rate. After 21 days, the estrogen pellets were
removed in half the mice and these mice were then treated
with the antiestrogen ICI 182,781. Tumors arising from
cells treated with collagen I alone regressed, while colla-
gen + laminin-treated tumor growth stabilized in response
to antiestrogen treatment (Haslam and Woodward,
unpublished data). In contrast, the tumors arising from
laminin-treated MCF-7 cells continued to grow in the pres-
ence of the antiestrogen, with tumor size increasing more
than 2-fold in 3 weeks. These results indicate that the
composition of ECM that surrounds tumor cells in vivo,
can affect their estrogen responsiveness and may be an
important mechanism underlying antiestrogen resistance
in human breast cancer.
Summary and conclusion
Breast cancer is frequently classified by ER status, since
absence of hormone responsiveness is associated with a
poor prognosis and substantially limits therapy options.
Treatment of breast cancer with selective estrogen recep-
tor modulators has met with limited success, partially
because 40% of tumors are ER negative, 33% of ER posi-
tive tumors do not respond to endocrine therapy and all
patients with advanced breast cancer on antiestrogen
therapy eventually experience progression while on treat-
ment, becoming antiestrogen resistant [18,23–26]. Our
understanding, therefore, of the acquisition of hormone
responsiveness in the normal breast and the loss of
responsiveness in advanced breast cancer is critical to
developing therapeutics to treat this disease. Acquisition
and loss of estrogen action are complex events involving
breast epithelial cells, their extracellular environment and
signals from stromal cells. The studies we have described
herein demonstrate that ECM proteins and their cellular
receptors, integrins, may be critical for acquisition and
loss of ovarian steroid function in normal and breast
cancer cells. Furthermore, ovarian steroids regulate ECM
protein and integrin expression in the mammary gland.
These data indicate that the substantial changes in ECM
protein expression that occur during breast cancer devel-
opment and progression may directly influence tumor
growth and ovarian steroid responsiveness. Advancing our
understanding of the acquisition and loss of ovarian
hormone status will be important in developing effective
therapies for the treatment of breast cancer.
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